MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ZYXI stock logo

ZYXI

Zynex, Inc.

$0.14
0.01
 (11.75%)
Exchange:  NASDAQ
Market Cap:  4.102M
Shares Outstanding:  4192
Delayed data
Calculate ZYXI Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – DistributionView industry performance
   
CEO:  Thomas Sandgaard
Full Time Employees:  1000
Address: 
9655 Maroon Circle
Englewood
CO
80112
US
Website:  https://www.zynex.com
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ZYZYXI logoZYXIZynex, Inc.4.1M——243.4%
AHAHG logoAHGAkso Health Group624.3M—0.2-56.7%
HSHSIC logoHSICHenry Schein, Inc.9.8B25.016.06.5%
CACAH logoCAHCardinal Health, Inc.51.6B30.320.413.2%
COCOR logoCORCencora, Inc.59.1B22.717.012.8%
MCMCK logoMCKMcKesson Corporation100.3B23.122.027.9%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/04/29 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202220232024
Revenue158,167184,322192,354
Gross Profit126,162145,956152,925
EBITDA22,93815,00010,791
Operating Income22,93810,7805,990
Net Income17,0489,7322,994

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202220232024
Total Assets116,466136,904122,079
Total Liabilities50,10890,77586,371
Total Stockholders Equity66,35846,12935,708
Total Debt26,95976,16873,824
Cash and Cash Equivalents20,14444,57939,631

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202220232024
Operating Cash Flow13,74617,94612,721
Capital Expenditure-418-1,206-578
Free Cash Flow13,32816,74012,143
Net Income17,0489,7322,994
Net Change in Cash-22,46824,435-4,948

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)130,268.886Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)136,631.465Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)133,199.999Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)16,595.502Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)17,406.058Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)16,968.909Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-4,339.370Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)-4,078.717Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-4,198.870Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)89,188.600Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)93,544.740Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)91,195.387Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-0.130Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)-0.130Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.130Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
192.354M  ?P/S
 (TTM)
: 
0.04
?Net Income
 (TTM)
: 
2.994M  ?P/E
 (TTM)
: 
-0.05
?Enterprise Value
 (TTM)
: 
62.158M  ?EV/FCF
 (TTM)
: 
-2.96
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-1807.05%  ?ROIC
 (TTM)
: 
243.35%
?Net Debt
 (TTM)
: 
34.193M  ?Debt/Equity
 (TTM)
: 
-1.73
?P/B
 (TTM)
: 
-0.09  ?Current Ratio
 (TTM)
: 
0.47

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates ZYXI intrinsic value between $5.53 – $5.67 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ZYXI valuation

Is Zynex, Inc. (ZYXI) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Zynex, Inc. (ZYXI) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ZYXI a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ZYXI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ZYXI’s P/E ratio?

You can see ZYXI’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ZYXI?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ZYXI a good long-term investment?

Whether ZYXI fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ZYXI

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

11.75
MARKETSnap

Trading Metrics:

Open: 0.1   Previous Close: 0.12
Day Low: 0.1   Day High: 0.14
Year Low: 0.06   Year High: 8.45
Price Avg 50: 0.93   Price Avg 200: 1.78
Volume: 751921   Average Volume: 298969

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Kuehn Law Encourages Investors of Zynex, Inc. to Contact Law Firm
13-07-2026 16:14
Kuehn Law Encourages Investors of Zynex, Inc. to Contact Law Firm

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read